Ultimovacs ASA announced a plan to optimize its business operations to support the continuous advancement of UV1 and long-term business growth. The operational adjustments enable an extension of the financial runway to the fourth quarter of 2025, beyond the anticipated topline readout from the Phase II DOVACC trial. Based on current plans and forecasts, the cash burn rate is estimated to be approximately NOK 15 million per quarter towards the end of 2025, prior to the initiation of potential new activities towards new clinical trials or other projects.
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
6.98 NOK | +0.29% | -11.65% | -94.32% |
Apr. 17 | Ultimovacs to Reduce 40% of Workforce Amid Operational Adjustments | MT |
Apr. 17 | Transcript : Ultimovacs ASA - Special Call |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-94.32% | 21.69M | |
+0.16% | 42.19B | |
+44.30% | 40.15B | |
-6.20% | 28.31B | |
+5.91% | 24.63B | |
-24.40% | 18.2B | |
+26.55% | 12.01B | |
-3.46% | 11.76B | |
+9.94% | 10.4B | |
-1.91% | 9.94B |
- Stock Market
- Equities
- ULTI Stock
- News Ultimovacs ASA
- Ultimovacs ASA Implements Operational Adjustments to Support Continuous Advancement of the UV1 Vaccine Phase II Program